TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

EMBEDA

MORPHINE SULFATE
Approved 2009-08-13
2
Indications
--
Phase 3 Trials
1
Priority Reviews
16
Years on Market

Details

Status
Discontinued
First Approved
2009-08-13
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

EMBEDA Approval History

Loading approval history...

What EMBEDA Treats

2 FDA approvals

Originally approved for its first indication in 2009 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EMBEDA FDA Label Details

Pro

EMBEDA Patents & Exclusivity

Latest Patent: Nov 2029

Patents (252 active)

US8623418 Expires Nov 7, 2029
US7815934 Expires Dec 12, 2027
US7682633 Expires Jun 19, 2027
US8158156 Expires Jun 19, 2027
US7682634 Expires Jun 19, 2027
US8846104 Expires Jun 19, 2027
US8877247 Expires Jun 19, 2027
+ 242 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.